Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 4/20 | 0.42 |
| ▸ | BRD2 | P25440 | 1/20 | 0.42 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5148164 | 0.85 | BRD4 (0.44) | BRD4BRD2BRD3CREBBPALB | |
| SCHEMBL5147135 | 0.84 | HDAC1 (0.43) | CREBBPGRM4MAOB | |
| SCHEMBL5145355 | 0.80 | GRM4 (0.35) | GRM4MAOB | |
| SCHEMBL5145359 | 0.80 | GRM4 (0.35) | GRM4MAOB | |
| SCHEMBL5148480 | 0.75 | PTGS1 (0.44) | GRM4 | |
| SCHEMBL5147134 | 0.74 | LMNA (0.45) | BRD4CREBBPGRM4MAOB | |
| SCHEMBL14422443 | 0.72 | TP53 (0.41) | BRD4CREBBPGRM4MAOBGRM1 | |
| SCHEMBL5147107 | 0.72 | CYP2D6 (0.48) | — | |
| SCHEMBL5148161 | 0.71 | TP53 (0.41) | BRD4CREBBPGRM4MAOB | |
| SCHEMBL5145428 | 0.71 | DOT1L (0.45) | CREBBPGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185184-A1 | Carbazole derivatives | SERENEX, INC. | 2007-08-09 | — | — | US | claimed |
| US-20070185184-A1 | Carbazole derivatives | SERENEX, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185184-A1 | Carbazole derivatives | SERENEX, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070185184-A1 | Carbazole derivatives | SERENEX, INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007035620-A2 | CARBAZOLE DERIVATIVES | SERENEX, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185184-A1 | Carbazole derivatives | CCNI, MKI67, CCNB3 | BRD4 189/4885BRD2 599/4885BRD3 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.